SCNX

COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three months ended March 31, 2026. Q1 2026 Financial Highlights Compared to Q1 2025: Revenue increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the prior-year three-month period, representing an increase of approximately 449% year-over-year, reflecting incremental product orders for ArbliTM in addition to the initial launch quantities ordered in the fourth quarter of 2025 Gross profit increased substantially to approximately $54 thousand, compared to approximately $673 in the prior-year three-month period, representing an increase of approximately 7900% year-over-year, primarily as a result of the increase in ArbliTM product orders Gross margin expanded to approximately 95.6% for the three months ended March 31, 2026, compared to approximately 6.6% in the prior-year three-month period, also as a result of the increase in ArbliTM product orders Key Operational Highlights in Q1 2026 and Subsequent Events: United States Patent and Trademark Office (USPTO) granted a third patent covering ArbliTM (losartan potassium) oral suspension, further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041 Received an Orange Book-listable patent for REZENOPYTM (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone HCl nasal spray for emergency opioid overdose treatment Formalized multiple commercial GPO agreements for REZENOPYTM, expanding access to over 5,000 healthcare institutions and reaching approximately 60% of the U.S. institutional market, including first responders, EMS providers, and rehabilitation centers Secured $11.0 Million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of R&D pipeline Narasimhan Mani, President and Co-CEO of Scienture, commented, “Our financial results for the quarter reflect the early progress of our co...

COMMACK, N.Y. (AP) — COMMACK, N.Y. (AP) — Scienture Holdings, Inc. (SCNX) on Friday reported a loss of $3.4 million in its first quarter. On a per-share basis, the Commack, New York-based company said it had a loss of 8 cents. The company posted revenue of $56,000 in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SCNX at https://www.zacks.com/ap/SCNX

Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the year ended December 31, 2025. 2025 Financial Highlights Compared to 2024: Net revenue increased 216% to $431,609 from $136,643 Gross Margin Expanded by 7,240 Basis Points to 76.8% Excluding a one-time, non-cash impairment charge of $26.3 million, net loss from continuing operations improved by approximately $37,000 year-over-year As of December 31, 2025, the company had cash and cash equivalents of approximately $6.7 million and positive working capital of approximately $5.2 million Key Operational Highlights in 2025 and Subsequent Events: Secured multiple PBM-led GPO rebate agreements, supporting expanded commercial coverage and formulary placement for Arbli™ Executed institutional GPO agreements, expanding U.S. access to more than 2,500 healthcare institutions nationwide for Arbli™ Achieved formulary inclusion with major national health plans for Arbli™, extending coverage to over 100 million lives Received an Orange Book-listable patent for Arbli™ (losartan potassium) Oral Suspension, 10mg/mL, the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market for treating hypertension, reinforcing and expanding Scienture’s intellectual property position Established a strategic collaboration with BlinkRx for Arbli™ to enhance patient access, fulfillment, and adherence through an integrated digital pharmacy and hub services platform Received an Orange Book-listable patent for REZENOPY™ (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone HCl nasal spray for emergency opioid overdose treatment Formalized multiple commercial GPO agreements for REZENOPY™, expanding access to over 5,000 healthcare institutions and reaching approximately 60% of the U.S. institutional market, including first responders, EMS providers, and rehabilitation centers Management Commentary Narasimhan Mani, President and Co-CEO of Scienture...

COMMACK, N.Y. (AP) — COMMACK, N.Y. (AP) — Scienture Holdings, Inc. (SCNX) on Monday reported a loss of $28.1 million in its fourth quarter. The Commack, New York-based company said it had a loss of $1.76 per share. For the year, the company reported a loss of $41.5 million, or $2.70 per share. Revenue was reported as $432,000. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SCNX at https://www.zacks.com/ap/SCNX

COMMACK, N.Y. (AP) — COMMACK, N.Y. (AP) — Scienture Holdings, Inc. (SCNX) on Wednesday reported a loss of $3.6 million in its third quarter. On a per-share basis, the Commack, New York-based company said it had a loss of 19 cents. The company posted revenue of $590,100 in the period. Its adjusted revenue was $590,000. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SCNX at https://www.zacks.com/ap/SCNX

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli™, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension COMMACK, NY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Compared to Third Quarter 2024: Launched sales of Arbli™ (losartan potassium). Net revenue increased from approximately $65 thousand to $590 thousand. Gross profit increased from approximately $4 thousand to $575 thousand. “Q3 was a transformational quarter for Scienture as we commenced sales of Arbli™,” commented Narasimhan Mani, President and Co-CEO of Scienture. “We delivered strong results this quarter, with significant increases in net revenues and gross profit as we entered full commercial scale-up of our first FDA-approved product, Arbli™. In the past month, Arbli™ was added to key national payor formularies, expanding access to over 100 million covered lives, and we secured GPO agreements reaching more than 2,500 healthcare institutions, representing potential penetration into roughly 20% of the U.S. institutional market. As we broaden our marketing efforts and demand builds across retail, institutional, and long-term care channels, we see significant potential for sustained adoption and long-term value creation. Subsequent to the end of the third quarter, we fundamentally strengthened our balance sheet by substantially reducing our outstanding debt and significantly enhancing our cash position to over $8 million as of November 13, 2025. Having optimized our capital structure, we are now strongly positioned and adequately capitalized to advance our commercial and operational priorities.” “Backed by a strong commercial infrastructure and the successful launch of Arbli™, Scienture is preparing to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment, in Q1 2026,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture...

Explore Scienture Holdings's Fair Values from the Community and select yours Net loss: US$6.72m (loss widened by 314% from 2Q 2024). US$0.47 loss per share. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Scienture Holdings shares are down 46% from a week ago. You should learn about the 5 warning signs we've spotted with Scienture Holdings (including 4 which shouldn't be ignored). Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

TAMPA, Fla. (AP) — TAMPA, Fla. (AP) — Scienture Holdings, Inc. (SCNX) on Tuesday reported a loss of $6.7 million in its second quarter. On a per-share basis, the Tampa, Florida-based company said it had a loss of 48 cents. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SCNX at https://www.zacks.com/ap/SCNX